A Convergent Bioengineered Platform for Multifunctional Therapeutic Exosomes
A Convergent Bioengineered Platform for Multifunctional Therapeutic Exosomes
批准号:
10713513
负责人:
Yichun Wang
金额:
$37.09万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-01 至 2028-06-30
关键词:
AddressAntineoplastic AgentsBiomanufacturingBiomedical EngineeringBioreactorsClinicClinicalCombined Modality TherapyDendrimersDevelopmentDiameterDiseaseDrug Delivery SystemsEndowmentEngineeringEukaryotic CellFormulationGene DeliveryGoalsHybridsLigandsLiposomesMolecularNatural regenerationNear-infrared optical imagingNeoplasm MetastasisNucleic AcidsPharmaceutical PreparationsPhenotypePlayPolymersProductionPropertyProteinsQuantum DotsRNAResearchSystemTechnologyTestingTherapeuticTherapeutic EffectTissuesToxic effectanticancer activitybiomaterial compatibilityblood-brain barrier crossingblood-brain barrier penetrationcancer therapycomparative efficacydelivery vehicleengineered exosomesexosomeextracellular vesiclesgrapheneimage guidedimmunogenicityimprovedin vivoinnovationmanufacturenanocarriernanofibernanoparticlenanoscalenucleasenucleic acid-based therapeuticspharmacokinetics and pharmacodynamicsscaffoldtargeted deliverytherapeutic proteintranscriptomicsuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
A Convergent Bioengineered Platform for Multifunctional Therapeutic Exosomes
Abstract: The overall goal of this MIRA application is to develop a convergent bioengineered platform for
manufacturing and engineering therapeutic exosomes. The platform will allow the loading of drugs into exosomes
with high efficiency, biomanufacturing of exosomes in high throughput, and further engineering exosome-based
drug delivery systems for various diseases with desired functions including targeted delivery, tracking, and
combinational therapies. Exosomes are a subset of extracellular vesicles, with diameters between 50 nm and 150
nm, secreted by most eukaryotic cells. They are very promising drug delivery vehicles due to their small size,
biocompatibility, low immunogenicity, and reduced toxicity in comparison with synthetic nanoscale formulations
such as liposomes, dendrimers, and polymers. Delivery of anticancer drugs contained in exosomes demonstrated
improved pharmacokinetic and pharmacodynamic properties and enhanced anticancer activity in vivo compared
to free drug molecules. Loading of therapeutic nucleic acids into exosomes protects the nucleic acids from
nucleases and increases cellular uptake and the therapeutic effect due to specific molecular mechanisms of
exosome internalization. Exosomes can cross the blood brain barrier and penetrate deep tissues with improved
efficacy compared to that of synthetic nanocarriers. Moreover, they play a key role in cancer metastasis and
regeneration by inducing transcriptomic and phenotypic changes with their RNA and protein cargoes. Therefore,
they can potentially be reengineered for delivery of gene and protein therapeutics. However, there remain
fundamental challenges to the utilization of exosomes in the clinic: i) drug loading efficiency into exosomes is
very limited; ii) the production of exosomes has yet to reach sufficiently high throughput for clinical tests or even
further development; and iii) endowing exosomes with multiple abilities for satisfactory disease targeting,
tracking and combinational therapies is highly demanding. To address these challenges, the PI proposes the
following three projects: 1) Developing a high-efficiency exosome drug loading technology with chiral graphene
nanoparticles; 2) Developing an exosome production bioreactor with stimulating piezoelectric nanofibrous
scaffolds; and 3) Engineering hybrid exosomes as a multifunctional targeted delivery system with targeting
ligands and functional chiral graphene quantum dots for near-infrared imaging-guided photothermal cancer
therapies. The proposed research contains several innovative approaches of exosome production, loading and
engineering that, if successful and integrated, will provide a high-throughput and high-efficiency exosome
manufacturing platform for drug delivery, and expand exosome-based drug delivery to diverse biomedical and
clinic applications by combining the merits of both the native exosomes and synthetic nanoparticles.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Scalable Continuous Production Platform for Large-Scale Manufacturing of Therapeutic Exosomes
-
批准号:10739425
-
项目类别:
-
资助金额:$40.24万
-
财政年份:2023
-
负责人:Yichun Wang
-
依托单位:
海外基金